Clinical Trial Update: Long Acting Cabotegravir Plus Rilpivirine in People Living with HIV-1 Aged ≥ 60 Years for 24 Months. [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating long-acting cabotegravir plus rilpivirine in adults with HIV-1 aged 60 and older who have controlled viremia; the study is currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• APRETUDE (CABOTEGRAVIR)
• Edurant (rilpivirine)

Snippet

Sponsor: Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia | Conditions: HIV-1 Infected Adults with Controlled Viremia | Phase 4 | Status: RECRUITING